DK3664800T3 - Terapeutiske formuleringer omfattende COX-2-inhibitor og anvendelse deraf - Google Patents

Terapeutiske formuleringer omfattende COX-2-inhibitor og anvendelse deraf Download PDF

Info

Publication number
DK3664800T3
DK3664800T3 DK18843332.0T DK18843332T DK3664800T3 DK 3664800 T3 DK3664800 T3 DK 3664800T3 DK 18843332 T DK18843332 T DK 18843332T DK 3664800 T3 DK3664800 T3 DK 3664800T3
Authority
DK
Denmark
Prior art keywords
cox
inhibitor
therapeutic formulations
formulations
therapeutic
Prior art date
Application number
DK18843332.0T
Other languages
English (en)
Inventor
Douglas Hepler
Gail L Dempsey
Roland Johnson
Michael Kelly
Michael Daniel
Neil E Paulsen
Bert Clayton
Original Assignee
Dechra Veterinary Products Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dechra Veterinary Products Llc filed Critical Dechra Veterinary Products Llc
Application granted granted Critical
Publication of DK3664800T3 publication Critical patent/DK3664800T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18843332.0T 2017-08-09 2018-08-09 Terapeutiske formuleringer omfattende COX-2-inhibitor og anvendelse deraf DK3664800T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762543215P 2017-08-09 2017-08-09
US201762594399P 2017-12-04 2017-12-04
PCT/US2018/046130 WO2019032910A1 (en) 2017-08-09 2018-08-09 THERAPEUTIC FORMULATIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
DK3664800T3 true DK3664800T3 (da) 2024-07-22

Family

ID=65272625

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18843332.0T DK3664800T3 (da) 2017-08-09 2018-08-09 Terapeutiske formuleringer omfattende COX-2-inhibitor og anvendelse deraf

Country Status (13)

Country Link
US (3) US20190142789A1 (da)
EP (2) EP3664800B1 (da)
JP (2) JP2020530462A (da)
AU (2) AU2018313933B2 (da)
CA (1) CA3072335A1 (da)
DK (1) DK3664800T3 (da)
ES (1) ES2984268T3 (da)
FI (1) FI3664800T3 (da)
HR (1) HRP20241063T1 (da)
HU (1) HUE068027T2 (da)
PL (1) PL3664800T3 (da)
PT (1) PT3664800T (da)
WO (1) WO2019032910A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023501207A (ja) * 2019-11-01 2023-01-18 ピードモント アニマル ヘルス インコーポレイテッド 治療用製剤およびその使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
NZ270145A (en) * 1994-03-01 1996-08-27 Lilly Co Eli Non-aqueous pharmaceutical formulation for oral administration comprising water-insoluble active agent, fatty acid solubilising agent, an oil and a surface active agent
GB9804886D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
US20040105885A1 (en) * 2001-04-17 2004-06-03 Ping Gao Gelatin capsule exhibiting reduced cross-linking
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
US20040138296A1 (en) * 2002-08-12 2004-07-15 Pharmacia Corporation Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050107349A1 (en) * 2003-07-24 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
DE602004025151D1 (de) * 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Fgf−20の調合物、生成方法および使用
EP2089010A1 (en) * 2006-10-24 2009-08-19 The John Hopkins University Rapid release mini-tablets provide analgesia in laboratory animals
WO2010128095A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Ectoparasiticidal compositions
CA2808978A1 (en) * 2010-08-23 2012-03-01 Shmuel Ben-Sasson Compositions for gastric delivery of active agents
CN110292575B (zh) * 2011-10-18 2022-05-13 株式会社AskAt 药物组合物
CA2886276A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
JP6777734B2 (ja) * 2015-06-10 2020-10-28 ピードモント アニマル ヘルス インコーポレイテッド 注射可能な抗生物質製剤及びその使用
WO2018165477A1 (en) * 2017-03-10 2018-09-13 Piedmont Animal Health, Llc Injectable antibiotic formulations and use thereof
US10555899B2 (en) * 2017-06-05 2020-02-11 Piedmont Animal Health, Llc Long-acting non-aqueous injectable formulations and use thereof

Also Published As

Publication number Publication date
CA3072335A1 (en) 2019-02-14
WO2019032910A1 (en) 2019-02-14
PT3664800T (pt) 2024-08-14
ES2984268T3 (es) 2024-10-29
AU2018313933A1 (en) 2020-03-12
HUE068027T2 (hu) 2024-12-28
JP2023134739A (ja) 2023-09-27
EP3664800A4 (en) 2021-09-01
AU2018313933B2 (en) 2024-03-07
EP3664800A1 (en) 2020-06-17
HRP20241063T1 (hr) 2024-11-08
FI3664800T3 (fi) 2024-08-07
JP2020530462A (ja) 2020-10-22
EP4389147A3 (en) 2024-10-23
PL3664800T3 (pl) 2024-11-18
AU2024203213A1 (en) 2024-05-30
EP4389147A2 (en) 2024-06-26
US20240100014A1 (en) 2024-03-28
US20230285354A1 (en) 2023-09-14
US20190142789A1 (en) 2019-05-16
EP3664800B1 (en) 2024-05-08

Similar Documents

Publication Publication Date Title
IL282487A (en) Tyk2 inhibitors and uses thereof
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3774789T3 (da) BRM-målrettede forbindelser og tilhørende fremgangsmåder til anvendelse
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
LT3452485T (lt) Arginazės inhibitoriai ir jų terapinis taikymas
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
DK3134061T3 (da) Peroxidformuleringer og fremgangsmåder og applikatorer til anvendelse heraf
DK3430129T3 (da) Kolonidannende medium og anvendelse deraf
DK3638251T3 (da) Bisphosphocin gel formuleringer og brug deraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3423076T3 (da) Topisk cyclosporinholdige formuleringer og anvendelser deraf
DK3710485T3 (da) Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3720875T3 (da) Antimikrobielle peptider og fremgangsmåder til anvendelse deraf
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf